MINI REVIEW article
Front. Pharmacol.
Sec. Ethnopharmacology
Abhraka Bhasma (Mica based Nanomedicine): An Ayurvedic Herbomineral Perspective in Breast Cancer Management
Provisionally accepted
Dhanya S1,2*
Amarnath K R3- 1Amrita Vishwa Vidyapeetham University, Coimbatore, India
- 2Department of Rasashastra and Bhaishajya kalpana, Amrita School of Ayurveda, Amritapuri, Amrita Vishwa Vidyapeetham, India, Kollam, India
- 3Department of Computer Science and Engineering, Amrita school of Computing, Amritapuri, Amrita Vishwa Vidyapeetham, India, Kollam, India
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background Abhraka Bhasma (Mica nanoparticles) is an Ayurvedic herbomineral medicine traditionally used in the management of conditions similar to breast cancer. Its rationale is based on its Dhatu-Pushtikara (tissue-nourishing), Rasayana (rejuvenating) and Tridosha-balancing properties, suggesting its potential for evaluation in integrative oncology. Objective This work aims to examine the therapeutic potential of Mica nanoparticles (Abhraka Bhasma) as an alternative medicine in the management of breast cancer. Methods (type of evidence) This mini-review analyses the preclinical and limited clinical evidence supporting Abhraka Bhasma (mica nanoparticles) as a potential adjunct in breast cancer management. The mechanistic basis was evaluated from in vitro and in vivo models. Key findings In vitro, Abhraka Bhasma exhibits dose-dependent cytotoxicity, apoptosis, immunomodulatory activity and inhibition of teratoma-formation in different cell lines In vivo studies support these findings, indicating enhanced DNA repair capacity, reduced genotoxicity, chemopreventive responses, immunostimulatory effects and modulation of oxidative stress. Conclusion The traditional Ayurvedic rationale for Abhraka Bhasma correlates with reported preclinical mechanisms. Thus, the ancient wisdom and modern evidence make Abhraka Bhasma an important part of integrative oncology, which offers a complementary strategy to improve patient outcomes. Available evidence on Abhraka Bhasma in cancer treatment is currently preclinical data (Level 5) and hypothesis generating only. To date, no RCTs or cohort studies (Levels 1-3) on the safety and efficacy of Abhraka Bhasma as an adjunct in breast cancer treatment have been published. To bridge the gap between traditional use and evidence based clinical application, a structured and systematic research pathway is essential.
Keywords: Abhraka bhasma, breast cancer, alternative medicine, Immunomodulation, Genotoxicity
Received: 09 Jul 2025; Accepted: 29 Nov 2025.
Copyright: © 2025 S and K R. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Dhanya S
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.